Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19
Younès Steffens, Serge-Daniel Le Bon, Jerome Lechien, Léa Prunier, Alexandra Rodriguez, Sven Saussez, Mihaela Horoi, Younès Steffens, Serge-Daniel Le Bon, Jerome Lechien, Léa Prunier, Alexandra Rodriguez, Sven Saussez, Mihaela Horoi
Abstract
Introduction: Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD), lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results.
Methods: In the present study, we investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD by the Sniffing Stick test (TDI score) and a linker-scale from 0 (none) to 3 (strong) and we compare the result to a control group.
Results: At 1 month post-PRP injection, the mean TDI scores significantly improved by 6.7 points in the PRP group (p < 0,001), the mean self-assessment of improvement in smell function was 1.8 (mild-to-moderate) in the PRP group, which was significantly higher than the score (0.3) in the control group (p < 0,001).
Conclusion: Our results showed that PRP in the olfactory cleft can increase the olfactory threshold 1 month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment, because no adverse effects were reported throughout the study.
Trial registration number: NCT05226546.
Keywords: Anosmia; COVID-19; Chronical olfactory dysfunction; Platelet rich plasma.
Conflict of interest statement
The author declares that they have no conflict of interest.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Figures
References
- Aziz M, Goyal H, Haghbin H, Lee-Smith WM, Gajendran M, Perisetti A. The association of “loss of smell” to COVID-19: a systematic review and meta-analysis. Am J Med Sci. 2021;361(2):216–225. doi: 10.1016/j.amjms.2020.09.017.
- Boscolo-Rizzo P, Guida F, Polesel J, et al. Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study. Eur Arch Oto-Rhino-Laryngol. 2021 doi: 10.1007/s00405-021-06839-w.
- Yan CH, Mundy DC, Patel ZM. The use of platelet-rich plasma in treatment of olfactory dysfunction: a pilot study. Laryngoscope Investig Otolaryngol. 2020;5(2):187–193. doi: 10.1002/lio2.357.
- Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, McCoul ED. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol Neck Surg. 2021;164(2):244–254. doi: 10.1177/0194599820943550.
- De Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021;13(596):eabf8396. doi: 10.1126/scitranslmed.abf8396.
- Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794. doi: 10.3390/ijms21207794.
- Farrag TY, Lehar M, Verhaegen P, Carson KA, Byrne PJ. Effect of platelet rich plasma and fibrin sealant on facial nerve regeneration in a rat model. Laryngoscope. 2007;117(1):157–165. doi: 10.1097/01.mlg.0000249726.98801.77.
- Kim DH, Lee MH, Lee J, Song EA, Kim SW, Kim SW. Platelet-rich plasma injection in patients with atrophic rhinitis. ORL J Otorhinolaryngol Relat Spec. 2021;83(2):104–111. doi: 10.1159/000513099.
Source: PubMed